Advancing immunization research in the Eastern Mediterranean Region: Launch of the Regional Research Working Group Authors: Palwasha Anwari, Ghassan S Dbaibo, Ahmed R Alsuwaidi, Quamrul Hasan, Osama Mere, Arshad Altaf, Aarti Singh, Ziad A Memish Published: 2026 A timely initiative for a complex region Research and the evidence it generates are fundamental to advancing global health and improving health equity. The World Health Organization (WHO) Eastern Mediterranean Region (EMR), comprising 22 countries and territories and home to approximately 745 million people [1], spans from Morocco in North Africa to Pakistan in South Asia and encompasses some of the world’s most diverse health system, socioeconomic, and epidemiological contexts [Fig. 1]. Geographical map of the World Health Organization (WHO)-Eastern Mediterranean Region (EMR) Countries N.B. WHO-EMR countries include Afghanistan; Bahrain; Djibouti; Egypt; Iran (Islamic Republic of); Iraq; Jordan; Kuwait; Lebanon; Libya; Morocco; Oman; Pakistan; occupied Palestinian territory (oPt), East Jerusalem; Qatar; Saudi Arabia; Somalia; Sudan; Syrian Arab Republic; Tunisia; United Arab Emirates; Yemen Source: Reproduced from Moghnieh et al. Antimicrobial Resistance & Infection Control (2023) 12:90. https://doi.org/10.1186/s13756-023-01299-9 [2]. The Region includes high-income countries with advanced immunization programmes, middle-income countries undergoing vaccine transition and financing reforms, and several low-income and fragile settings affected by protracted conflict, displacement, and humanitarian emergencies. Despite substantial progress in reducing vaccine-preventable diseases, including an estimated one-third reduction in infant mortality since the expansion of immunization programmes in the 1970 [3,4], the EMR continues to face persistent and complex challenges. These include inequitable access to vaccines, suboptimal routine immunization coverage, recurrent outbreaks of vaccine-preventable diseases, and the broader effects of fragile health systems, humanitarian crises, population displacement, and sociopolitical instability. Emerging and evolving public health threats further underscore the urgency of strengthening evidence generation in the Region. These include the resurgence of measles ongoing risks of circulating vaccine-derived poliovirus, alongside growing interest in the introduction of new and underutilized vaccines such as those targeting dengue and respiratory syncytial virus (RSV), and tuberculosis. In parallel, the MER’s proximity to regions affected by emerging pathogens, including Ebola virus disease, and its experience with zoonotic and epidemic-prone infections such as Middle East Respiratory Syndrome (MERS), reinforce the need for timely, context-specific, and policy-relevant evidence to guide immunization strategies. Despite these challenges, and the presence of substantial technical expertise across Member States, the Region has historically lacked a coordinated mechanism to systematically generate, prioritize, synthesize, and translate immunization research into policy and practice. In February 2025, during its meeting in Cairo, Egypt, the Regional Immunization Technical Advisory Group (RITAG) recommended establishing a regional Working Group on Research (WG-Research) to strengthen the generation and application of context-specific evidence for immunization. This commentary outlines the rationale, scope, and anticipated impact of WG-Research, and argues that such mechanisms are essential to advancing immunization equity and strengthening system resilience throughout the EMR. The WG-Research is composed of experts nominated through RITAG, ensuring broad and balanced representation from national immunization programmes, National Immunization Technical Advisory Groups (NITAGs), research institutions, academia, independent researchers, and WHO technical units. Membership is based on technical expertise and regional representation rather than country quotas, ensuring both scientific rigor and inclusivity across diverse settings. Members are selected based on expertise in immunization research, epidemiology, implementation science, health economics, and vaccine policy. This multidisciplinary and regionally representative composition enables the group to integrate scientific, programmatic, and policy perspectives, thereby fostering collaboration, facilitating knowledge exchange, and strengthening evidence-informed decision-making across Member States and partners. Mandate and scope WG-Research will serve as a regional platform for implementation and operational research by identifying priority questions, fostering collaboration, and facilitating the translation of the evidence into policy. Guided by comprehensive Terms of Reference (ToR), the group will deliver a biennial workplan, a five-year research agenda, annual landscape analyses, alongside technical briefs tailored for decision-makers. Its scope is broad yet targeted, covering implementation research, vaccine-preventable disease burden, surveillance systems, behavioral and social drivers of immunization, vaccine effectiveness and safety, health economics, and digital innovations. Through a structured framework (Fig. 2), WG-Research will support a continuous cycle of evidence generation, knowledge translation, and policy integration, ensuring that research outcomes directly contribute directly to programme improvement and immunization equity. Regional Working Group on Research (WG-Research): Core domains and framework for advancing immunization research in the Eastern Mediterranean Region. The WG-Research functions as a digital and collaborative platform for implementation research, coordination, and evidence translation across six strategic domains: (1) burden of vaccine-preventable diseases (VPDs) and surveillance, (2) behavioural and social drivers, (3) equity and gender, (4) health economics and value for money, (5) innovation and digital tools, and (6) pandemic preparedness and immunization. Together, these pillars drive knowledge generation, evidence use, and policy impact, ultimately reinforcing immunization equity and system resilience in the Region. Expected outcomes include strengthened VPD surveillance systems, adapted WHO’s Behavioral and Social Drivers (BeSD) frameworks to address hesitancy, gender-sensitive equity analyses, integration of cost-effectiveness evidence into NITAG recommendations, deployment of digital innovations for monitoring and forecasting, and operational guidance to embed immunization within preparedness frameworks. Rationale for establishing WG-Research Although global investment in vaccine research has expanded over the recent decades [5,6], supported by initiatives such as Gavi, the vaccine alliance, Coalition for Epidemic Preparedness Innovations (CEPI), and WHO, major regional disparities remain. Much of evidence base continue to originate from high-income settings, limiting its applicability to diverse and often fragile context of EMR. The COVID-19 pandemic revealed the consequences of uneven research capacity. Countries with strong research ecosystems were able to generate and apply local evidence to guide vaccine rollout, while others relied heavily on external data that were not always contextually relevant. Embedding WG-Research within RITAG provides a structured platform to define regional priorities, coordinate research efforts, reduce fragmentation, and accelerate the translation of evidence into immunization policy and practice. Contextual relevance and country ownership A defining feature of WG-Research is its emphasis on contextual relevance and country ownership. Through structured consultations with Member States, the group will ensure that research priorities reflect national realities and respond directly to local needs. This bottom-up approach aligns with global strategies such as the Immunization Agenda 20230 (IA203), which emphasizes country-driven research agendas and the use of evidence to inform implementation and improve programme performance [7]. Building regional research capacity Sustainable progress requires long-term investment in human capital and institutional capacity. WG-Research will prioritize capacity building through mentorship, modular training packages, and e-learning in research methods, ethics, and data use. Fostering collaboration between countries will further support knowledge exchange and skill development. In settings where shortages of skilled researchers and limited institutional infrastructure persist, these investments are critical for building resilient research ecosystems and enabling countries to generate, interpret, and apply their own evidence. Governance and transparency The WG-Research ToR establishes a robust governance framework. Deliverables such as a biennial workplan, regional research agenda aligned with the strategic priority 7 (research and innovation) of IA2030 [7], and annual landscape analyses will function as strategic tools for aligning priorities, guiding resource allocation, and tracking progress. A formal Code of Conduct, including requirement for integrity, confidentiality, and disclosure of conflicts of interest, will help ensure transparency and reinforce the scientific independence of the group. Strategic focus areas for impact WG-Research will prioritize a set of domains with high regional relevance: •Burden of vaccine-preventable diseases and surveillance: A priority area for new and emerging vaccines expected to be introduced in the coming decade, where data from the region remain limited. Burden of vaccine-preventable diseases and surveillance: A priority area for new and emerging vaccines expected to be introduced in the coming decade, where data from the region remain limited. •Behavioral and social drivers: Misinformation, hesitancy, and demand-side barriers remain pervasive. Applying WHO’s Behavioral and Social Drivers (BeSD) framework [8], WG-Research will adapt and apply these tools to EMR contexts. Behavioral and social drivers: Misinformation, hesitancy, and demand-side barriers remain pervasive. Applying WHO’s Behavioral and Social Drivers (BeSD) framework [8], WG-Research will adapt and apply these tools to EMR contexts. •Equity and gender: Immunization programmes must be inclusive, reaching marginalized populations, displaced groups, and those affected by conflict. Research highlighting disparities and informing targeted interventions will be essential for achieving IA2030 goals [7,9]. Equity and gender: Immunization programmes must be inclusive, reaching marginalized populations, displaced groups, and those affected by conflict. Research highlighting disparities and informing targeted interventions will be essential for achieving IA2030 goals [7,9]. •Health economics and value-for-money: With constrained fiscal space, evidence on cost-effectiveness and financing is critical for sustainable immunization strategies [10]. Health economics and value-for-money: With constrained fiscal space, evidence on cost-effectiveness and financing is critical for sustainable immunization strategies [10]. •Innovation and digital tools: Exploring digital health applications for surveillance, demand generation, and monitoring will support both programme performance and accountability. Innovation and digital tools: Exploring digital health applications for surveillance, demand generation, and monitoring will support both programme performance and accountability. •Pandemic preparedness and immunization: The COVID-19 pandemic exposed vulnerabilities in vaccine delivery systems. Generating evidence around emerging and reemerging diseases to integrate immunization within broader preparedness plans is a timely and vital focus [11]. Pandemic preparedness and immunization: The COVID-19 pandemic exposed vulnerabilities in vaccine delivery systems. Generating evidence around emerging and reemerging diseases to integrate immunization within broader preparedness plans is a timely and vital focus [11]. Sustainability, independence, and regional ownership Sustainability is both a challenge and an imperative for long-term success of WG-Research. The Working Group will operate within WHO and RITAG governance structure, leveraging in-kind contributions and partnerships with academic institutions, national programmes, and regional networks. Scientific independence will be maintained through strict adherence to WHO conflict-of-interest policies, with research priorities and recommendations developed through transparent, evidence-based processes independent of commercial interests. Embedding WG-Research within regional systems, promoting south–south collaboration, and strengthening country ownership will be essential to ensure long-term impact and sustainability. Global alignment and outlook WG-Research will collaborate closely with WHO-EMRO technical units, mainly science, innovation, and data for impact (SID) department and the immunization system strengthening and accelerated disease control (ISS-ADC), and partners to ensure alignment with global standards and maximize the visibility and uptake of regional evidence. By strengthening the research–policy interface, the group has the potential to position the EMR as an active contributor to global immunization research and innovation efforts. Conclusion The establishment of WG-Research under RITAG representing a timely and strategic response to the complex immunization challenges facing the EMR. Anchored in collaboration, context relevance, and capacity strengthening, it offers a practical mechanism to bridge the gap between research and policy. If successfully implemented, WG-Research could serve as a model for other WHO regions seeking to strengthen evidence-informed immunization policy through regionally led, collaborative research platforms. CRediT authorship contribution statement Palwasha Anwari: Writing – original draft. Ghassan S. Dbaibo: Writing – review & editing. Ahmed R. Alsuwaidi: Writing – review & editing. Quamrul Hasan: Writing – review & editing. Osama Mere: Writing – review & editing. Arshad Altaf: Writing – review & editing. Aarti Singh: Writing – review & editing. Ziad A. Memish: Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Contributor Information Palwasha Anwari, Email: palwashanwari@gmail.com, anwarip@who.int. Ahmed R. Alsuwaidi, Email: alsuwaidia@uaeu.ac.ae. Quamrul Hasan, Email: quamrulh@gmail.com. Osama Mere, Email: mereo@who.int. Arshad Altaf, Email: altafa@who.int. Aarti Singh, Email: singhaa@who.int. Ziad A. Memish, Email: zmemish@yahoo.com. References